Stock OXFD OXFORD IMMUNOTEC GLOBAL PLC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Oxford Immunotec Global PLC

Equities

OXFD

GB00BGFBB958

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oxford Immunotec Announces Use of T-SPOT®Discovery SARS-CoV-2 Kit
CI
Oxford Immunotec Global PLC will Change its Name to Oxford Immunotec Global Limited
CI
Oxford Immunotec Global PLC Announces Board Changes
CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from S&P Global BMI Index
CI
Oxford Immunotec Global PLC(NasdaqGM:OXFD) dropped from NASDAQ Composite Index
CI
PerkinElmer (UK) Holdings Limited completed the acquisition of Oxford Immunotec Global PLC.
CI
Oxford Immunotec Global PLC's Equity Buyback announced on January 7, 2019, has expired.
CI
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
CI
Oxford Immunotec Global : Plans to Market T Cell Immune Response Measurement Kit to COVID-19 in South Korea
MT
Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea
GL
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea
CI
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses
GL
Oxford Immunotec Updates Their T-SPOT® Discovery SARS-Cov-2 Kit and Include New Panel to Detect T Cells Reactive to Endemic Coronaviruses
CI
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
GL
OXFORD IMMUNOTEC INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oxford Immunotec Global PLC - OXFD
BU
Oxford Immunotec Global : Teams With Valneva on COVID-19 Vaccine Candidate Testing
MT
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study
GL
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study
CI
Sector Update: Health Care Stocks Add to Early Rise, Supported by Biotech Companies
MT
Sector Update: Modest Advance for Health Care Stocks Despite Larger Gains for Biotechnology Sector
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OXFD Stock
  4. News Oxford Immunotec Global PLC